Hey everyone! In this video, I discuss the relationship history between Amarin and the FDA regarding their EPA medication (Vascepa) for the lowering of triglycerides. I believe the difficulty #AMRN has had with the FDA in the past has made the market concerned about Vascepa’s future given recent announcement of an advisory committee meeting for […]
Category: Uncategorized
045 – Gilead PrEP Revenue in JEOPARDY!
Hey everybody, today I talk about the upcoming advisory committee meeting, which will lead to a recommendation (or not) for the approval of Descovy for pre-exposure prophylaxis (PrEP) in high-risk individuals. I also go through the latest ICER reports on AIMT and AMRN. I mention a short-term trade idea but remember to do your own […]
044 – Marker Therapeutics DISAPPOINTS in pancreatic cancer
Hi all, today I talk about the #MRKR interim update of their MultiTAA treatment in pancreatic cancer. I go through the data in all 3 arms and analyze whether or not they see an actual effect of their unique therapy. *this is not investment advice* #breaking biotech #biotech
042 – Biotech M&As accelerate. IMMU’s ADC shakes up breast cancer!
Today, I cover the latest in biotech with a highlight on Immunomedics and their antibody-drug conjugates for breast cancer. *this is not investment advice* http://www.breakingbiotech.com @matthewlepoire
041 – Is REGENXBIO a buy after Zolgensma approval?
Today, I talk about REGENXBIO and their in-house gene therapy candidates. Their most important asset in early clinical trials is RGX-314, indicated for wet AMD (and hopefuily Diabetic Retinopathy). This gene therapy could replace blockbuster drugs that treat millions patients, but is it a buy today? Follow me @matthewlepoire http://www.breakingbiotech.com *this is not investment advice*
040 – Biogen faces another headwind with Zolgensma approval
Hi all, I’m back today talking about the approval of Avexis/Novartis’ gene therapy for spinal muscular atrophy, Zolgensma. I also talk about how I came to a conclusion about whether or not I should short Biogen. Follow me on twitter @matthewlepoire http://www.breakingbiotech.com *this is not investment advice*
039 – Will Marker Therapeutics Succeed in Pancreatic Cancer?
Hi everybody, in this episode I take a deeper dive into pancreatic cancer and how Marker Therapeutics’ MultiTAA T Cell therapy might fare against it. Thanks for watching! Follow me on twitter @matthewlepoire Note: *This is not investment advice*
038 – Democrats scare the healthcare sector plus Marker Therapeutics breakdown
Hey all, tonight I talk about the latest downswing in biotech/pharma and I breakdown Marker Therapeutics. This company has a novel platform to activate T cells for cancer treatment that significantly reduces side effects, which are common in CAR-T. I jumbled over explaining target optimization. Basically, the company is using the same antigen targets to […]
036 – End of Q1-19 Biotech Updates
Happy Sunday everyone! Today, I talk about: -#BIIB/Eisai and their decision to continue trials with compounds that reduce brain amyloid beta -ESSENCE interim data from #SRPT -The #VKTX abstract release and upgrade -More good news about #AMRN This is not investment advice, so do your own due diligence! http://www.breakingbiotech.com #breakingbiotech #biotech
035 – Trevena upside potential and more Amarin
Today I go through a trading idea for Trevena as well as the updated Amarin data. This is not investment advice. http://www.breakingbiotech.com
